DAYBREAK decides the Kodiak story
- Kodiak has no approved products and has not generated revenue, so the stock depends on clinical and regulatory wins.
- Zenkuda, also called tarcocimab, looked much better in diabetic retinopathy after GLOW2 met its main goal with no intraocular inflammation reported.
- The next big test is DAYBREAK, a Phase 3 wet AMD study expected to report topline data in 3Q 2026.
- The bear case is still real because tarcocimab missed key wet AMD goals in DAZZLE, GLEAM, and GLIMMER.
- KSI-501, KSI-101, ABCD, and VETi add options, but none remove the near-term need for clean data and FDA trust.
One trial carries the weight
Kodiak is a high-risk retina drug story. The good news is that Zenkuda, its lead drug also known as tarcocimab, has shown it can work with less frequent dosing in diabetic retinopathy. In GLOW2, the drug met its primary endpoint, met secondary goals, and reported no intraocular inflammation.
That matters because retina patients often need repeated eye injections. A drug that can last about 6 months in the right setting could be valuable if doctors trust the data and regulators approve the label.
The hard part is wet AMD. Tarcocimab already failed to show non-inferior vision gains in the DAZZLE, GLEAM, and GLIMMER wet AMD studies. DAYBREAK is the repair attempt, using an enhanced 50 mg/mL formulation and also testing KSI-501, a VEGF and IL-6 blocker.
So the thesis is simple. If DAYBREAK is clean and regulators accept the bridge from the old formulation to the go-to-market material, Kodiak may have a real retina franchise. If not, the company is left with earlier programs and a damaged lead asset.
Science first, sales later
Kodiak does not sell an approved product today. It is spending money to run trials, improve drug designs, and prepare for a possible Biologics License Application, which is the FDA filing used for biologic drugs.
The company is built around its ABC Platform. That platform links protein drugs to a biopolymer backbone, with the goal of keeping the drug active in the eye for longer. The newer ABCD Platform extends that idea to small molecules and other active ingredients.
If approved, Kodiak would make money from retina drug sales, either by building its own commercial team, using partners, or some mix of both. Until approval, the business breaks if trial results are weak, regulators reject the data package, or cash runs too low before approval.
Retina shots and new tools
Zenkuda, or tarcocimab
This is Kodiak's lead anti-VEGF antibody biopolymer conjugate. It has completed GLOW2 in diabetic retinopathy and is in DAYBREAK for wet AMD, with a planned 2026 BLA across DR, RVO, and wet AMD if the data support it.
KSI-501
KSI-501 is a first-in-class bispecific conjugate meant to block VEGF and IL-6. It is being studied in DAYBREAK for wet AMD, where Kodiak hopes dual inhibition can help patients who need more than standard VEGF control.
KSI-101
KSI-101 is a VEGF-trap and anti-IL-6 bispecific protein for retinal inflammatory disease. The PEAK and PINNACLE Phase 3 studies are actively enrolling patients with macular edema secondary to inflammation.
KSI-102 and KSI-103
These are pre-IND ocular inflammation programs. KSI-102 targets TNFa and IL-6, while KSI-103 targets IL-1 and IL-6.
ABCD glaucoma and dry AMD programs
The ABCD Platform adds preclinical shots on goal in glaucoma and dry AMD. These are early, but they could matter if the platform proves it can deliver sustained release beyond the first retina drugs.
VETi headset
VETi is an AI and machine-learning enabled wearable headset. Kodiak sees it as a possible support tool for a future commercial retina franchise, not as a main business today.
One operating segment
Kodiak reports as one operating segment focused on research, development, and possible commercialization of retinal disease therapies. As of the latest internal filing view, it had no approved commercial products and had not generated revenue, so the mix below is shown as operating focus rather than revenue mix.
What could break
DAYBREAK misses in wet AMD
High impact · Medium oddsThis is the main near-term risk. Tarcocimab already missed primary wet AMD efficacy goals in DAZZLE, GLEAM, and GLIMMER, so investors need DAYBREAK to show that the new plan fixed the problem.
FDA rejects the formulation bridge
High impact · Medium oddsKodiak changed to an enhanced 50 mg/mL formulation for the go-to-market version of Zenkuda. The FDA has advised that added studies should be enough to bridge old and new material, but Kodiak says regulators may still disagree.
AI dosing tool creates label friction
Medium impact · Medium oddsDAYBREAK uses an AI-based tool to measure retinal fluid and personalize dosing. Management now warns that this dosing approach may not make it into labeling or may require separate FDA review of the AI tool.
Safety signal returns
High impact · Low oddsGLOW2 was encouraging because no intraocular inflammation was reported. Eye drugs have little room for safety surprises, since doctors may avoid a drug that risks inflammation or vision harm.
Pipeline options stay too early
Medium impact · Medium oddsKSI-101, KSI-501, ABCD, KSI-102, KSI-103, and VETi add breadth. But most of that value is still not proven by approval or sales. If the lead program stumbles, these assets may not be mature enough to carry the company.
In one breath
Does Kodiak Sciences have any approved products?
No. Kodiak is still a clinical-stage company, and its filings say it has no approved products for commercial sale and has not generated revenue.
What is the main Kodiak Sciences catalyst?
The main catalyst is the Phase 3 DAYBREAK wet AMD readout, expected in 3Q 2026. A positive result could support a planned single BLA across diabetic retinopathy, retinal vein occlusion, and wet AMD.
Why did tarcocimab become controversial?
Tarcocimab showed promise, but it previously failed to meet key wet AMD endpoints in DAZZLE, GLEAM, and GLIMMER. GLOW2 helped the diabetic retinopathy case, but DAYBREAK still has to repair confidence in wet AMD.